查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1641778

全球升糖素市場按產品類型、應用和分銷管道分類 - 機會分析和產業預測，2024-2033 年

Glucagon Market By Product Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計升糖素市場規模在 2023 年將達到 3 億美元，到 2033 年將達到 6 億美元，2024 年至 2033 年的複合年成長率為 6.4%。

胰高血糖素市場-IMG1

升糖素是胰臟 α 細胞產生的肽激素。它在葡萄糖代謝中發揮重要作用，當血糖值血糖值過低時，它可以升高血糖，並維持體內的能源平衡。這種荷爾蒙主要作用於肝臟，促進肝醣的分解（肝醣分解）並刺激非碳水化合物來源產生葡萄糖（糖質新生）。升糖素可對抗胰島素，降低血糖值。

全球糖尿病（尤其是第 1 型糖尿病）盛行率的驚人上升推動了對升糖素的需求，因為它是治療嚴重低血糖的關鍵治療方法。國際糖尿病聯盟 (2023) 估計，全球有超過 5.4 億成年人患有糖尿病，凸顯了升糖素治療的重要性。此外，醫療機構在低血糖管理方面的教育工作也促使升糖素製劑的採用率增加，尤其是對於發生嚴重低血糖事件風險較高的糖尿病患者。此外，老年人口的快速增加是全球市場的主要動力。隨著世界人口老化，越來越多的人面臨糖尿病和相關併發症的風險，從而推動了對升糖素產品的需求。世界衛生組織（WHO）2024年發布的一項研究顯示，老年人口數量將從2020年的10億增加到2030年的14億。此外，到2050年，80歲及以上人口數量預計將達到4.26億人。此外，升糖素不僅用於降血糖，而且擴大被用於診斷成像（例如放射學和內視鏡檢查）以放鬆消化道，擴大其市場範圍。然而，升糖素療法，尤其是較新的劑型如鼻內升糖素，價格昂貴，並且可能成為獲得治療的重大障礙，特別是對於低收入社區或缺乏足夠醫療保險的患者而言。升糖素的使用，特別是在緊急情況下，通常需要醫療保健專業人員的指導才能正確使用，這可能會進一步限制其在無法立即獲得醫療救助的情況下的使用。同時，預填充式注射器、自動注射器和鼻內升糖素製劑等技術創新使得給藥變得更加容易，使患者和看護者能夠更方便、更輕鬆地接受升糖素治療。預計這些發展將為預測期內全球市場的擴張開闢新的途徑。

全球升糖素產業分為類型、應用、分銷管道和地區。根據類型，市場分為注射升糖素和鼻用升糖素。根據應用分為低血糖症和診斷支持。根據分銷管道，分為醫院藥局、零售藥局和網路藥局。按地區分析，涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲。

主要發現

根據類型，注射胰高升糖素預計將在 2024 年至 2033 年期間佔據市場主導地位。

根據應用，預計預測期內低血糖症領域在全球市場將呈現成長。

根據分銷管道，醫院藥房部門預計在整個預測期內將以驚人的速度成長。

從地理上看，升糖素市場預計將在北美實現強勁成長。

此報告可自訂。 （需支付額外費用和時間安排。）

  • 監管指南
  • 根據客戶興趣加入公司簡介
  • 擴展公司簡介列表
  • 贖回情況

目錄

第 1 章 簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 重大投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會

第 4 章升糖素市場（依產品類型）

  • 市場概況
  • 注射用胰高升糖素
  • 鼻用胰高升糖素

第 5 章升糖素市場：按應用

  • 市場概況
  • 低血糖
  • 診斷輔助工具

第6章升糖素市場依通路分類

  • 市場概況
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 7 章升糖素市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國升糖素市場
    • 加拿大升糖素市場
    • 墨西哥的升糖素市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國升糖素市場
    • 德國升糖素市場
    • 義大利升糖素市場
    • 西班牙的升糖素市場
    • 英國升糖素市場
    • 其他歐洲國家升糖素市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國的升糖素市場
    • 日本升糖素市場
    • 印度升糖素市場
    • 韓國胰升糖素市場
    • 澳洲升糖素市場
    • 其他亞太地區胰高升糖素市場
  • 拉丁美洲、中東和非洲
    • 主要市場趨勢和機遇
    • 巴西的升糖素市場
    • 南非胰升糖素市場
    • 沙烏地阿拉伯的升糖素市場
    • 其他拉丁美洲、中東和非洲升糖素市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 前 10 家公司的產品映射
  • 競爭儀錶板
  • 競爭熱圖
  • 2023年主要企業的定位

第9章 公司簡介

  • Novo Nordisk A/S
  • Fresenius SE And Co. KGaA
  • Amphastar Pharmaceuticals, Inc.
  • Xeris Biopharma Holdings, Inc.
  • ILS Inc
  • United Biotech（P）Limited
  • Zealand Pharma A/S
  • Taj Pharmaceuticals Limited
  • Eli Lilly And Company.
  • Pfizer Inc.
簡介目錄
Product Code: A324426

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Glucagon Market - IMG1

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Product Type

  • Injectable Glucagon
  • Nasal Glucagon

By Application

  • Hypoglycemia
  • Diagnostic Aid

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Novo Nordisk A/S
    • Fresenius SE & Co. KGaA
    • Amphastar Pharmaceuticals, Inc.
    • Xeris Biopharma Holdings, Inc.
    • ILS Inc
    • United Biotech (P) Limited
    • Zealand Pharma A/S
    • Taj Pharmaceuticals Limited
    • Eli Lilly and Company.
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Injectable Glucagon
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nasal Glucagon
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypoglycemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostic Aid
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Product Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Glucagon Market
      • 7.2.6.1. Market Size and Forecast, By Product Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Glucagon Market
      • 7.2.7.1. Market Size and Forecast, By Product Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Glucagon Market
      • 7.2.8.1. Market Size and Forecast, By Product Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Product Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Glucagon Market
      • 7.3.6.1. Market Size and Forecast, By Product Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Glucagon Market
      • 7.3.7.1. Market Size and Forecast, By Product Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Glucagon Market
      • 7.3.8.1. Market Size and Forecast, By Product Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Glucagon Market
      • 7.3.9.1. Market Size and Forecast, By Product Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Glucagon Market
      • 7.3.10.1. Market Size and Forecast, By Product Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest Of Europe Glucagon Market
      • 7.3.11.1. Market Size and Forecast, By Product Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Product Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Glucagon Market
      • 7.4.6.1. Market Size and Forecast, By Product Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Glucagon Market
      • 7.4.7.1. Market Size and Forecast, By Product Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Glucagon Market
      • 7.4.8.1. Market Size and Forecast, By Product Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Glucagon Market
      • 7.4.9.1. Market Size and Forecast, By Product Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Glucagon Market
      • 7.4.10.1. Market Size and Forecast, By Product Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Glucagon Market
      • 7.4.11.1. Market Size and Forecast, By Product Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Product Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Glucagon Market
      • 7.5.6.1. Market Size and Forecast, By Product Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Glucagon Market
      • 7.5.7.1. Market Size and Forecast, By Product Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Glucagon Market
      • 7.5.8.1. Market Size and Forecast, By Product Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Glucagon Market
      • 7.5.9.1. Market Size and Forecast, By Product Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping Of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novo Nordisk A/S
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Fresenius SE And Co. KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Amphastar Pharmaceuticals, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Xeris Biopharma Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. ILS Inc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. United Biotech (P) Limited
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Zealand Pharma A/S
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Taj Pharmaceuticals Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments